Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy.
| Ticker |
Sentiment |
Impact |
|
AKESF
|
Neutral
|
19 %
|
|
TIL
|
Somewhat Bearish
|
10 %
|
|
BNTX
|
Neutral
|
10 %
|
|
SMMT
|
Somewhat Bullish
|
24 %
|
